Colgate-Palmolive (NYSE:CL) Price Target Raised to $100.00 at Citigroup

Colgate-Palmolive (NYSE:CL) had its target price hoisted by investment analysts at Citigroup from $95.00 to $100.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target points to a potential upside of 16.05% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Raymond James upgraded Colgate-Palmolive from a “market perform” rating to an “outperform” rating and set a $91.00 price objective for the company in a research report on Monday, January 29th. The Goldman Sachs Group began coverage on Colgate-Palmolive in a research report on Friday, March 1st. They set a “buy” rating and a $93.00 price objective for the company. UBS Group boosted their price objective on Colgate-Palmolive from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, January 29th. Stifel Nicolaus boosted their price objective on Colgate-Palmolive from $89.00 to $94.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Finally, Barclays upped their target price on Colgate-Palmolive from $82.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Friday. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, Colgate-Palmolive currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.50.

Colgate-Palmolive Stock Up 0.4 %

Shares of Colgate-Palmolive stock opened at $86.17 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 1.11 and a debt-to-equity ratio of 8.59. The firm has a market cap of $70.83 billion, a P/E ratio of 31.00, a P/E/G ratio of 3.26 and a beta of 0.42. Colgate-Palmolive has a fifty-two week low of $67.62 and a fifty-two week high of $90.37. The business has a 50-day moving average price of $86.87 and a 200 day moving average price of $80.48.

Colgate-Palmolive (NYSE:CL) last posted its earnings results on Friday, January 26th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.85 by $0.02. The company had revenue of $4.95 billion during the quarter, compared to analyst estimates of $4.89 billion. Colgate-Palmolive had a return on equity of 509.75% and a net margin of 11.82%. The business’s revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.77 earnings per share. On average, sell-side analysts forecast that Colgate-Palmolive will post 3.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Colgate-Palmolive

In other news, insider Jennifer Daniels sold 61,633 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $83.93, for a total value of $5,172,857.69. Following the transaction, the insider now directly owns 57,948 shares of the company’s stock, valued at $4,863,575.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Jennifer Daniels sold 61,633 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $83.93, for a total value of $5,172,857.69. Following the transaction, the insider now directly owns 57,948 shares of the company’s stock, valued at $4,863,575.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director C Martin Harris sold 2,760 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $84.50, for a total transaction of $233,220.00. Following the completion of the transaction, the director now directly owns 19,272 shares in the company, valued at $1,628,484. The disclosure for this sale can be found here. Insiders have sold a total of 232,371 shares of company stock valued at $19,505,099 in the last three months. 0.37% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Colgate-Palmolive

Several hedge funds have recently bought and sold shares of the business. OFI Invest Asset Management bought a new stake in Colgate-Palmolive during the third quarter valued at about $25,000. Union Savings Bank raised its position in Colgate-Palmolive by 76.6% in the fourth quarter. Union Savings Bank now owns 309 shares of the company’s stock worth $25,000 after purchasing an additional 134 shares in the last quarter. Garner Asset Management Corp acquired a new position in Colgate-Palmolive in the fourth quarter worth about $30,000. Avion Wealth increased its holdings in shares of Colgate-Palmolive by 78.1% during the fourth quarter. Avion Wealth now owns 399 shares of the company’s stock worth $32,000 after buying an additional 175 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC acquired a new stake in shares of Colgate-Palmolive during the fourth quarter worth approximately $32,000. 80.41% of the stock is owned by institutional investors and hedge funds.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.